Breaking: FDA approves Biogen's controversial Alzheimer's drug

The drug, which will be marketed as Aduhelm, is the first ever that US regulators say can treat... If you are having trouble viewing this email, click here.

JUN 07, 2021   It's the first federally approved treatment in almost two decades   The drug, which will be marketed as Aduhelm, is the first ever that US regulators say can treat the underlying disease and its memory-robbing effects, rather than just symptoms like anxiety and insomnia. Read More     Advertisement       The email address for your subscription is edwardlorilla1991.magnifiecientnews@blogger.com Manage Email Preferences or Unsubscribe   For more New York Post, download the New York Post App:

Follow us on: New York Post 1211 Avenue of the Americas New York, NY 10036 USA © Copyright 2021 NYP Holdings, Inc. All rights reserved Privacy  |  Terms of Use  |  Your Ad Choices